Updated

Eli Lilly's CEO told CNBC that roughly one-third of new GLP-1 pill patients are now taking the company's Foundayo, as Lilly ramps up production to catch up with Novo Nordisk, which had a head start in the oral GLP-1 market. The comments highlight intensifying competition in the fast-growing weight-loss and diabetes drug segment. The update comes as Novo Nordisk separately faces investor skepticism over its own post-Wegovy growth strategy, underscoring how competitive dynamics in the GLP-1 market are shifting as rivals scale up alternative treatments.